Anodyne

Lorazepam
Generated by the Chemistry Development Kit (http://github.com/cdk)
Molecular structure via molpic based on CDK
[]
Conformer structure via JSmol
Physical properties
[]
335.2 g/mol [1]
Melting point206 °C [1]
2.4 [1]
Structural Identifiers
[]
C16H12Cl2N2O2 [1]
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3H-1,4-benzodiazepin-2-one [1]
CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3Cl [1]
InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3 [1]
InChIKeyFJIKWRGCXUCUIG-UHFFFAOYSA-N [1]
Dosing
[]
Elimination half-life10 – 12 hours

Lorazepam

Lorazepam (also known as Lorazepam, Lormetazepam, Methyllorazepam, N-Methyllorazepam, Loramet, Noctamid, Lormetazepamum, Chlorotemazepam, Ergocalm or Noctamide) is a substance of the benzodiazepine class.

Chemistry

 []

Lorazepam is a racemic mixture of the optical stereoisomers

Stereoisomers
(+)-LorazepamGenerated by the Chemistry Development Kit (http://github.com/cdk)
(-)-LorazepamGenerated by the Chemistry Development Kit (http://github.com/cdk)
Anodyne Usernotes
[]
0xea / Lorazepam via ; Strong

Legal status []

  • Brazil: Lorazepam is a B1 substance.[3]
  • Canada: Lorazepam is a Schedule IV substance.
  • Germany: Lorazepam is a prescription only/Anlage III substance.
  • United States: Lorazepam is a Schedule I under the "Controlled Substances Act (CSA)".

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 13314, Lorazepam. Accessed July 11, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/13314

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lorazepam. UNII: GU56C842ZA. Global Substance Registration System. Accessed July 11, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/GU56C842ZA

  3. Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed July 11, 2025. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992